Differentiated expression of long non-coding RNA-small nucleolar RNA host gene 8 in atherosclerosis and its molecular mechanism

Figures & data

Table 1. Basic clinical information of the subjects

Indicators	Control (n = 84)	Atherosclerosis (n = 83)	P value
Gender (males/females)	47/37	46/37	0.945
Age (years)	53.80 (6.57)	53.75 (6.17)	0.959
BMI (kg m^−2)	25.08 (2.07)	25.46 (2.26)	0.256
TC (mg dl^−1)	195.85 (16.93)	201.29 (30.26)	0.153
HDL (mg dl^−1)	50.50 (5.28)	49.23 (8.31)	0.241
LDL (mg dl^−1)	120.33 (15.21)	124.45 (18.98)	0.123
TG(mg dl^−1)	145.41 (19.79)	151.73 (29.08)	0.102
FBG(mmol l^−1)	5.45 (0.96)	5.47 (1.17)	0.917
SBP(mm Hg)	129.70 (18.22)	152.87 (20.31)	<0.001 (0.0000)
DBP(mm Hg)	83.50 (9.96)	89.17 (9.64)	<0.001 (0.0002)
cfPWV (m s^−1)	6.54 (1.70)	12.50 (3.52)	<0.001 (0.0000)
CIMT (mm)	0.60 (0.15)	1.23 (0.14)	<0.001 (0.0000)

Abbreviations: BMI, body mass index; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low density lipoprotein; TG, triglyceride; FBG, fasting blood-glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; cfPWV, carotid-femoral pulse wave velocity; CIMT, carotid intima-media thickness. Data are expressed as n or mean (standard deviation).

Figure 1. LncSNHG8 expression was increased in AS patients. ***P < 0.001

Figure 2. Receiver operating characteristic curve analysis of the AUC, specificity, and sensitivity of lncSNHG8 in AS

Table 2. Correlation between lncRNA SNHG8 and clinical characteristics

Characteristics	Correlation with lncRNA SNHG8 (r)	P-value
TC (mg dl^−1)	0.132	0.235
HDL (mg dl^−1)	−0.052	0.642
LDL (mg dl^−1)	0.168	0.129
TG(mg dl^−1)	0.159	0.152
FBG(mmol l^−1)	0.032	0.776
SBP(mm Hg)	0.321	0.003
DBP(mm Hg)	0.515	<0.001
cfPWV (m s^−1)	0.792	<0.001
CIMT (mm)	0.720	<0.001

Abbreviations: TC, total cholesterol; HDL, high-density lipoprotein; LDL, low density lipoprotein; TG, triglyceride; FBG, fasting blood-glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; cfPWV, carotid-femoral pulse wave velocity; CIMT, carotid intima-media thickness.

Figure 3. (A) PCR analysis of down-regulation efficacy after transfection with si-SNHG8 in HA-VSMCs. (B) CCK-8 analysis of decreased cell viability in si-SNHG8 group. (C) Transwell analysis of reduced cell migration after transfected with si-SNHG8. (D) Transwell image of cell migration after transfected with si-SNHG8. ***P < 0.001

Figure 4. (A) The binding site of lncSNHG8 and miR-224-3p. (B) Luciferase activity analysis after co-transfected with WT or MUT vector and miR-224-3p mimic or inhibitor. (C) Serum miR-224-3p expression was decreased in AS patients. (D) Correlation analysis manifested that miR-224-3p was negatively correlated with lncSNHG8. (E) PCR analysis of overexpression efficacy of miR-224-3p after transfection with si-SNHG8 in HA-VSMCs. ***P < 0.001